Zila, Inc. announced that it has completed the first phase of marketing its proprietary oral cancer screening product, ViziLite Plus with TBlue. It has first marketed its product in North America and now it has spread through 50 states of the US, as well as Puerto Rico and Canada. Currently, the product is available in the United Kingdom, Ireland, Germany, Spain, Portugal, France and Greece. In the next step, the company has formed distribution agreements in other international markets, including Russia and Belarus, where product registration is in process. These markets and others in the Pacific Rim region, especially China and India, will form the bulk of the company’s continued global expansion for ViziLite Plus. ViziLite Plus is an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented vital tissue dye (TBlue) to help dentists and dental technicians identify and evaluate abnormalities in the mouth that could potentially harbor pathologic changes. The ViziLite Plus exam is painless, non-invasive and takes only few minutes.